AGIO
NASDAQAgios Pharmaceuticals Inc.
Price$39.58+6.31 (+18.97%)
2026-04-142026-07-17
News · 26 weeks64-76%
2026-01-252026-07-19
Mix3790d
- Insider19(51%)
- Other7(19%)
- SEC Filings6(16%)
- Earnings5(14%)
Latest news
25 items- INSIDERDirector Backstrom Jay T. was granted 1,447 shares (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRU.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell DiseaseFDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for this sNDA, submitted under the FDA’s accelera
- SECSEC Form SCHEDULE 13G filed by Agios Pharmaceuticals Inc.SCHEDULE 13G - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
- INSIDERChief Medical Officer Gheuens Sarah sold $150,503 worth of shares (4,007 units at $37.56) as part of a pre-agreed trading plan and converted options into 8,375 shares, increasing direct ownership by 5% to 84,645 units (SEC Form 4) to cover withholding tax4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRAgios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ETCAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 30, 2026, at 8:00 a.m. ET to report its second quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections t
- INSIDERDirector Ballal Rahul D. converted options into 2,816 shares, increasing direct ownership by 23% to 15,230 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Capello Jeffrey D converted options into 2,816 shares, increasing direct ownership by 35% to 10,865 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Foster-Cheek Kaye I converted options into 2,816 shares, increasing direct ownership by 38% to 10,284 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Fouse Jacqualyn A converted options into 2,816 shares, increasing direct ownership by 2% to 154,156 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Ho Maykin converted options into 2,816 shares, increasing direct ownership by 17% to 19,848 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Owen Adams Catherine converted options into 2,816 shares, increasing direct ownership by 35% to 10,865 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Scadden David converted options into 2,816 shares, increasing direct ownership by 16% to 20,419 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Smith Cynthia converted options into 2,816 shares, increasing direct ownership by 23% to 15,230 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Strategy and Operations Viswanadhan Krishnan4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Goff Brian4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Burns James William4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Gheuens Sarah4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Jones Cecilia4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Milanova Tsveta4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Director Backstrom Jay T.4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- SECSEC Form S-8 filed by Agios Pharmaceuticals Inc.S-8 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- SECSEC Form 8-K filed by Agios Pharmaceuticals Inc.8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- INSIDERDirector Owen Adams Catherine converted options into 1,976 shares, increasing direct ownership by 33% to 8,049 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERDirector Capello Jeffrey D converted options into 1,976 shares, increasing direct ownership by 33% to 8,049 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRAgios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell DiseaseMitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effectsNew analyses showed patients in mitapivat arm had clinically meaningful reduction in transfusion burden compared with placeboPatients in mitapivat arm who achieved hemoglobin response had clinically meaningful benefits across measures of sickle cell pain crises, fatigue, and other patient-reported outcomesMitapivat was well-tolerated, with a safety profile consistent with previous trials of mitapivat in sickle cell diseaseCompany to host investor conference call and webcast today at 9:00 a.m. ET (3:00 p.m. CEST) CAMBRIDGE, Mass., June 13, 2026 (GLO
AGIO FAQ
7 questionsWhat does Agios Pharmaceuticals Inc. do?
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat...Where does AGIO stock trade?
Agios Pharmaceuticals Inc. (AGIO) is listed on NASDAQ.What sector and industry is AGIO in?
Agios Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Agios Pharmaceuticals Inc. go public?
Agios Pharmaceuticals Inc. (AGIO) completed its IPO in 2013.What are analysts saying about AGIO?
Agios Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2026-04-20. Recent price targets range from $2800.00 to $3400.00.What companies are similar to AGIO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AGIO side-by-side with any of them on Quantisnow.How can I track AGIO on Quantisnow?
Quantisnow aggregates Agios Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AGIO to receive live email and push alerts on every new disclosure.